The estimated Net Worth of Lauren Merendino is at least $4.77 Milion dollars as of 18 January 2023. Lauren Merendino owns over 2,008 units of Myovant Sciences Ltd stock worth over $4,574,135 and over the last 4 years Lauren sold MYOV stock worth over $192,503.
Lauren has made over 4 trades of the Myovant Sciences Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently Lauren sold 2,008 units of MYOV stock worth $53,995 on 18 January 2023.
The largest trade Lauren's ever made was selling 7,049 units of Myovant Sciences Ltd stock on 19 April 2022 worth over $73,662. On average, Lauren trades about 1,558 units every 34 days since 2021. As of 18 January 2023 Lauren still owns at least 169,538 units of Myovant Sciences Ltd stock.
You can see the complete history of Lauren Merendino stock trades at the bottom of the page.
Lauren's mailing address filed with the SEC is C/O ESSA PHARMA INC., 999 WEST BROADWAY, SUITE 720, VANCOUVER, A1, V5Z 1K5.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... a Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: